VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Halmos on the Implications of the IPASS Study

Balazs Halmos, MD
Published: Wednesday, Mar 26, 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the implication of the IPASS study.

The IPASS study was a key study in the field, Halmos says, as it analyzed the EGFR inhibitor gefitinib compared with standard chemotherapy for patients with advanced lung adenocarcinoma without knowledge of EGFR mutation status.

Results of the study showed that the two groups fared similarly over the long term, but that there was a huge discrepancy between outcomes in patients with EGFR mutated and wild-type tumors. Patients treated with gefitinib demonstrated a 70-fold greater benefit in EGFR mutated tumors compared with wild-type. This group of patients also experienced quality of life benefits.

The IPASS study was the first that concluded there was a need to identify patients early on with EGFR mutations and ensure that they receive an upfront EGFR tyrosine kinase inhibitor.

Balazs Halmos, MD, section chief of Thoracic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the implication of the IPASS study.

The IPASS study was a key study in the field, Halmos says, as it analyzed the EGFR inhibitor gefitinib compared with standard chemotherapy for patients with advanced lung adenocarcinoma without knowledge of EGFR mutation status.

Results of the study showed that the two groups fared similarly over the long term, but that there was a huge discrepancy between outcomes in patients with EGFR mutated and wild-type tumors. Patients treated with gefitinib demonstrated a 70-fold greater benefit in EGFR mutated tumors compared with wild-type. This group of patients also experienced quality of life benefits.

The IPASS study was the first that concluded there was a need to identify patients early on with EGFR mutations and ensure that they receive an upfront EGFR tyrosine kinase inhibitor.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x